A perfusion machine and perfusion method for in vitro genetic modification
By incorporating a universal gene modification module and an external blood purification bypass module into the perfusion machine, along with a coordination control module, the problems of maintaining long-term perfusion steady state and exposing gene modification vectors in existing technologies have been solved, enabling stable gene modification and continuous maintenance of ex vivo organs.
Patent Information
- Application Number
- CN202611566179.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-10
- Publication Date
- 2026-11-10
AI Technical Summary
Existing NMP perfusion machines cannot maintain perfusion steady state for a long time. Urine reflux, dialysis or hemofiltration protocols are not linked to gene editing applications. There is a lack of unified connection and fault isolation among modules. Gene editing evaluation standards lack universality. Gene editing vectors and blood purification consumables lack a unified closed system, which may lead to the premature removal, adsorption or dilution of gene-modified vectors by dialysis or filtration.
A perfusion device is provided, comprising a main perfusion circuit, a universal genetic modification module, an external blood purification bypass module, a urine management module, a temperature regulation module, and a coordination control module. By setting the universal genetic modification module in the main perfusion circuit and connecting the external blood purification bypass module in parallel, and cooperating with the coordination control module, the device sequentially controls drug administration, effective exposure, blood purification, urine reflux, and temperature switching, enabling the carrier to act directly on the isolated organ at an appropriate time and restore purification and homeostasis support during the long-term maintenance phase.
It achieves stable gene modification and continuous maintenance of ex vivo organs under long-term perfusion conditions, supports both normothermic and cryogenic mechanical perfusion, ensures effective exposure and steady-state support of gene modification vectors, and avoids premature removal and dilution of vectors.
Smart Images

Figure CN123063276A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of biomedical instrument technology, and in particular to a perfusion machine and perfusion method for in vitro gene modification. Background Technology
[0002] Existing mechanical perfusion of ex vivo organs is mainly used for preservation, transportation, and pre-transplant functional assessment. The clinical and experimental feasibility of HMP / NMP has been confirmed by machine-controlled trials and systematic reviews. A 2023 randomized controlled trial of kidney transplantation (DOI: 10.1038 / s41591-023-02376-7, PMID: 37231075) and a 2024 meta-analysis of randomized controlled trials of mechanical kidney perfusion (DOI: 10.1093 / bjs / znae102, PMID: 38637312) show that temperature, oxygenation, pressure, flow rate, and perfusion fluid composition are the basic control variables for perfusion equipment.
[0003] Extending perfusion duration expands the organ intervention window from several hours to longer periods, but it also amplifies problems such as solute precipitation, changes in perfusion volume, nutrient depletion, and cytokine accumulation. Current research protocols for long-term renal non-perfusion medicine (NMP) primarily rely on urine reabsorption or urine replacement to maintain loop volume and electrolyte stability. A 24-hour NMP study of discarded human kidneys (DOI: 10.1111 / ajt.14932, PMID: 29758129) showed that urine refluxing is beneficial for maintaining physiological sodium concentrations; a porcine kidney study (DOI: 10.1097 / TXD.00000000000000985, PMID: 32309627) showed that the urine refluxing group achieved more stable blood flow, pH, and lactate levels, and prolonged the achievable perfusion time; a 48-hour NMP study of discarded human kidneys (DOI: 10.3389 / ti.2023.11804, PMID: 37901298) further demonstrated the feasibility of prolonged renal perfusion.
[0004] Urine recovery protocols can maintain water and partial metabolic stability, but they are essentially full or partial reinfusions and lack the ability to selectively remove solutes, by flow rate, and by time. In liver NMP, studies have shown that hemodialysis filters, continuous renal replacement therapy, or continuous venous hemofiltration are connected in parallel to the perfusion system. Lascaris et al. used a 0.2 m² small dialyzer for continuous ultrafiltration and fluid replacement, restoring the perfusion fluid composition to near physiological range within 12 hours and maintaining it for up to 7 days (DOI: 10.1097 / TXD.0000000000001568, PMID: 38274473); Huang et al. connected a dialysis filter in parallel to a commercial NMP system to remove water-soluble waste and regulate electrolytes at dialysate flow rates of 100 to 600 mL / h (DOI: 10.1111 / aor.14749, PMID: 38528752). Continuous blood filtration combined with a modified perfusion fluid formulation can also support human liver perfusion for 120 to 184 hours (DOI: 10.1038 / s43856-024-00636-2, PMID: 39448795).
[0005] Eshmuminov et al. reported an integrated perfusion device that simultaneously manages oxygenation, glucose, waste removal, and hematocrit, which can sustain a damaged human liver for one week (DOI: 10.1038 / s41587-019-0374-x, PMID: 31932726); the paper discloses the relevant patent application as PCT / EP2019 / 051252, and WIPO publication record as WO2019141809A1. The above technology demonstrates that "perfusion + waste removal" can prolong organ maintenance time, but its goal is organ preservation and homeostasis support. It does not address the possibility of genetically modified vectors being removed, adsorbed, or diluted by the dialysis membrane, nor does it disclose the synergistic state mechanism between drug administration, exposure, dialysis pause, dialysis resumption, and post-modification flushing.
[0006] Normative mechanical perfusion and in vitro gene delivery: There are precedents for cross-organ drug delivery via perfusion and organ gene delivery. A review of renal drug delivery (DOI: 10.3389 / fimmu.2021.673562, PMID: 34295329), a rat kidney LV-shB2M / LV-shCIITA perfusion study (DOI: 10.3389 / fimmu.2020.00265, PMID: 32140158), and a porcine lung vascular endothelial MHC silencing study (DOI: 10.1089 / hum.2018.117, PMID: 302) Studies such as siRNA targeting β2-microglobulin and CIITA in rat kidneys to alleviate acute rejection after kidney transplantation (DOI: 10.1097 / TP.0000000000005529; PMID: 41145403) and lentiviral delivery of NMP in rat liver over 72 hours (DOI: 10.1038 / s41434-025-00536-7, PMID: 40263629) support the feasibility of ex vivo perfusion as a delivery window for genetic modification. However, these studies are mostly organ-specific, vector-specific, and investigational circuits, and a universal machine structure capable of synergizing with long-term dialysis steady-state modules has not yet been established.
[0007] The existing technology has the following drawbacks:
[0008] (1) Traditional NMP perfusion machines cannot maintain perfusion steady state for a long time. During long-term perfusion, urea, phosphate, lactate, cytokines and other metabolites continue to accumulate, and osmotic pressure, electrolytes, acid-base and volume shift over time, limiting long-term gene modification processes that require waiting for gene expression, silencing or editing repair.
[0009] (2) Existing urine refluxing, dialysis, or hemofiltration protocols are for organ preservation purposes and have not yet been linked to gene editing applications. Hemodialysis may remove small molecule nucleic acids, transfection aids, nutrients, or cell activation inducers, and may also cause viruses, LNPs, and protein / RNPs to adsorb onto the filter and tubing surfaces.
[0010] (3) Existing NMP machines are usually temporarily connected in parallel, lacking organic series connection and fault isolation. Existing public solutions rarely uniformly specify the structural relationship of fluid collection point, fluid return point, main circuit bypass, drug administration point, urine return, ultrafiltration fluid replenishment, air bubble interception, transmembrane pressure alarm, and maintaining organ main perfusion when external equipment fails.
[0011] (4) Existing gene editing evaluation standards lack cross-platform universality. Technical pathways such as viral transduction, RNA interference, RNP delivery, base editing, and transient mRNA expression exhibit significant differences in molecular dynamics characteristics and phenotypic manifestation time windows. A reasonable system architecture should adhere to the principle of "separation of process control and result verification."
[0012] (5) Gene editing vectors, biosafety, and blood purification consumables have not yet formed a unified closed system. Viruses, nucleic acids / LNPs, RNPs, and dialysis waste liquids involve leakage, residue, cross-contamination, membrane adsorption, and waste liquid inactivation issues, respectively. Existing research loops lack unified batch traceability and disposable consumable connection. Summary of the Invention
[0013] The purpose of this invention is to provide a perfusion machine and method for in vitro gene modification, in order to solve the problems existing in the prior art. It supports gene modification of ex vivo organs by mechanical perfusion at both ambient temperature and low temperature. By setting a universal gene modification module in the main perfusion circuit and connecting an external blood purification bypass module in parallel, and coordinating with a control module to sequentially control drug administration, effective exposure, blood purification, urine reflux and temperature switching, the carrier can act directly on the ex vivo organ at an appropriate time. At the same time, purification and homeostasis support are restored during the long-term maintenance phase, thereby achieving stable gene modification and continuous maintenance of ex vivo organs under long-term perfusion conditions.
[0014] To achieve the above objectives, the present invention provides the following solution:
[0015] This invention provides a perfusion device for in vitro gene modification, comprising a main perfusion circuit, a universal gene modification module, an external blood purification bypass module, a urine management module, a temperature regulation module, and a coordination control module. The main perfusion circuit is used to continuously supply fluid to the isolated organ. The universal gene modification module is connected to the main perfusion circuit. The external blood purification bypass module is used to communicate with the main perfusion circuit and support long-term perfusion. The urine management module is also connected between the isolated organ and the main perfusion circuit. The coordination control module is signal-connected to the main perfusion circuit, the universal gene modification module, the external blood purification bypass module, the urine management module, and the temperature regulation module. The temperature control module is used to regulate the temperature of the perfusion fluid in the main perfusion circuit.
[0016] In one embodiment, the main perfusion circuit includes a reservoir, a main circulation pump, an oxygenator, a heat exchanger, a main circuit bubble trap, and an arterial pressure and flow monitoring unit connected in sequence. The end of the arterial pressure and flow monitoring unit is connected to the excised organ. The perfusion fluid of the excised organ is returned to the reservoir via a venous return line to form a closed-loop main circuit through the excised organ. A sampling port is provided on the venous return line.
[0017] In one embodiment, the universal gene modification module includes a vector cartridge, a quantitative drug delivery pump, and a vector injection and mixing unit. The vector is delivered from the vector cartridge to the vector injection and mixing unit via the quantitative drug delivery pump. The vector injection and mixing unit is connected in series after the main loop bubble trap.
[0018] In one embodiment, the external blood purification bypass is connected in parallel to the venous return line. The external blood purification bypass module includes a liquid extraction isolation valve, a bypass pump, an external blood purifier, a bypass bubble trap, and a return liquid isolation valve connected in sequence. A blood purification waste liquid collection bag is connected to the external blood purifier.
[0019] In one embodiment, the urine management module includes a urine inflow line and a urine return line, wherein the urine inflow line receives urine produced by the excised organ and returns it to the reservoir via the urine return line.
[0020] In one embodiment, a replenishment fluid branch is also included, wherein the replenishment fluid branch is a replenishment fluid bag, and the replenishment fluid bag is connected to the reservoir via a replenishment pipeline and replenishes the reservoir with fluid.
[0021] In one embodiment, a gas supply unit is further included, which is connected to the oxygenator via a gas passage and is used to supply the oxygenator with the gas required for filling.
[0022] In one embodiment, the temperature regulation module is connected to the heat exchanger via a temperature control circuit, and the temperature of the perfusion fluid in the main injection circuit is adjusted through the heat exchanger.
[0023] In one embodiment, the coordination control module is connected to the main circulation pump, the universal genetic modification module, the arterial pressure and flow monitoring unit, the urine management module, and the temperature regulation module via signal lines.
[0024] The present invention also provides a perfusion method for in vitro gene modification, applied to the above-mentioned perfusion machine for in vitro gene modification, comprising the following steps:
[0025] Step 1: Connect the reservoir, main circulation pump, oxygenator, heat exchanger, main loop bubble trap, carrier injection and mixing unit, arterial pressure and flow monitoring unit, venous return line and excised organ to form a closed main perfusion circuit;
[0026] Step 2: Connect the gas supply unit to the oxygenator, the temperature control module to the heat exchanger, the urine management module to the isolated organ and the reservoir, and connect the supplementary fluid bag to the reservoir;
[0027] Step 3: Depending on whether long-term perfusion is required, connect an external blood purification bypass module and confirm that the bypass includes, in sequence, a liquid intake isolation valve, a bypass pump, an external blood purifier, a bypass bubble trap, a return liquid isolation valve, and a blood purification waste liquid collection bag.
[0028] Step 4: Start the main circulation pump, gas supply unit and temperature regulation module to establish the main perfusion circulation; if blood purification is required in advance, open the liquid extraction isolation valve and the liquid return isolation valve and start the bypass pump;
[0029] Step 5: Enter the drug delivery state, close the liquid extraction isolation valve and the liquid return isolation valve and stop the bypass pump, place the gene modification vector in the vector cartridge, and deliver it to the vector injection and mixing unit by the quantitative drug delivery pump;
[0030] Step Six: Keep the main circulation pump running during effective exposure, allowing the carrier to enter the isolated kidney along with the perfusion fluid through the arterial pressure and flow monitoring unit; keep the external blood purification bypass module isolated;
[0031] Step 7: After completing the preset effective exposure, stop the metering pump, open the liquid intake isolation valve and the liquid return isolation valve, and start the bypass pump to put the machine into long-term maintenance mode;
[0032] Step 8: During the long-term maintenance process, urine is returned to the reservoir via the urine management module; when fluid replacement is needed, fluid is supplied to the reservoir from the fluid replacement bag;
[0033] Step 9: After the preset perfusion time is reached, the drug administration and blood purification are stopped. The temperature of the perfusion fluid is adjusted through the temperature regulation module, and the sample is obtained through the sampling port. The gene modification results are confirmed by an external method that matches the specific vector.
[0034] The present invention achieves the following technical effects compared to the prior art:
[0035] This invention relates to a perfusion device for in vitro gene modification, comprising a main perfusion circuit, a universal gene modification module, an external blood purification bypass module, a urine management module, a temperature regulation module, and a coordination control module. The main perfusion circuit continuously supplies fluid to the isolated organ. The universal gene modification module is connected to the main perfusion circuit. The external blood purification bypass module is connected to the main perfusion circuit and supports long-term perfusion. A urine management module is also connected between the isolated organ and the main perfusion circuit. The temperature control module is used to regulate the temperature of the perfusion fluid in the main perfusion circuit. This invention supports gene modification of isolated organs via both ambient temperature and cryogenic mechanical perfusion. By setting a universal gene modification module in the main perfusion circuit and connecting it in parallel with an external blood purification bypass module, and coordinating with the coordination control module to sequentially control drug administration, effective exposure, blood purification, urine reflux, and temperature switching, the carrier can directly act on the isolated organ at appropriate time intervals, while restoring purification and steady-state support during the long-term maintenance phase. This achieves stable gene modification and continuous maintenance of isolated organs under long-term perfusion conditions. Attached Figure Description
[0036] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0037] Figure 1 A schematic diagram of the overall structure of a perfusion machine used for in vitro gene modification;
[0038] In the diagram: 1. Liquid reservoir; 2. Main circulation pump; 3. Oxygenator; 4. Heat exchanger; 5. Main loop bubble trap; 6. Universal genetic modification module; 7. Vector cartridge; 8. Dosing pump; 9. Vector injection and mixing unit; 10. Arterial pressure and flow monitoring unit; 11. Ex vivo organ; 12. Venous return tubing; 13. Liquid extraction isolation valve; 14. Bypass pump; 15. External blood purifier; 16. Bypass bubble trap; 17. Return liquid isolation valve; 18. Urine management module; 19. Supplemental fluid bag; 20. Blood purification waste collection bag; 21. Coordination control module; 22. Gas supply unit; 23. Temperature regulation module; 24. Sampling port; 25. External blood purification bypass module. Detailed Implementation
[0039] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0040] Existing ex vivo organ perfusion technology is mainly used for organ preservation, transportation, and pre-transplant functional assessment. Although it can achieve normothermic / hypothermic perfusion and a certain degree of metabolic support, its structural design is still centered on "maintaining organ survival" and has not been synergistically designed around the goal of "long-term gene modification." The most significant drawback is that existing perfusion machines cannot simultaneously maintain homeostasis and effectively expose gene-modified vectors during long-term perfusion. The lack of clear temporal linkage between blood purification, urine refluxing, fluid replacement, and drug administration leads to the potential premature removal, adsorption, or dilution of gene-modified vectors by dialysis or filtration, thus reducing actual efficacy. Furthermore, existing systems often use temporary parallel connections between modules, lacking unified serial relationships, fault isolation mechanisms, and universal payload interfaces, and also lack compatibility design for different gene-modified vectors. Therefore, this invention proposes an ex vivo organ gene-modification machine that supports both ambient temperature and low temperature mechanical perfusion. By setting a universal gene-modification module in the main perfusion circuit and connecting an external blood purification bypass module in parallel, and coordinating with a control module to sequentially control drug administration, effective exposure, blood purification, urine reflux, and temperature switching, the carrier can directly act on the ex vivo organ at appropriate time periods, while restoring purification and steady-state support during the long-term maintenance phase. This achieves stable gene modification and continuous maintenance of ex vivo organs under long-term perfusion conditions.
[0041] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
[0042] like Figure 1 As shown, this invention provides a perfusion machine for in vitro gene modification, including a main perfusion circuit, a universal gene modification module 6, an external blood purification bypass module 25, a urine management module 18, a temperature regulation module 23, and a coordination control module 21. The main perfusion circuit is used to continuously supply fluid to the isolated organ 11. The universal gene modification module 6 is connected to the main perfusion circuit. The external blood purification bypass module 25 is used to communicate with the main perfusion circuit and support long-term perfusion. The urine management module 18 is also connected between the isolated organ 11 and the main perfusion circuit. The coordination control module 21 is signal-connected to the main perfusion circuit, the universal gene modification module 6, the external blood purification bypass module 25, the urine management module 18, and the temperature regulation module 23. The temperature control module is used to regulate the temperature of the perfusion fluid in the main perfusion circuit.
[0043] This invention is based on Figure 1 The main perfusion circuit shown serves as the framework, with the general gene-modification module 6 as the pre-organ insertion structure for gene modification, and an external blood purification bypass module 25 supporting long-term perfusion. The main perfusion circuit continuously supplies fluid to the isolated organ 11; the blood purification bypass module, urine management module 18, and supplemental fluid branch are all connected as shown in the figure, but without changing the continuity of the main perfusion circuit.
[0044] The coordination control module 21 is connected to the main circulation pump 2, the general genetic modification module 6, the arterial pressure and flow monitoring unit 10, the bypass pump 14, the urine management module 18, and the temperature regulation module 23 via control signals shown by the dashed lines in the figure. The controlled objects are limited to the start-up, shutdown, and sequential coordination of the modules shown in the figure; the genetic modification results are confirmed by external terminal methods and are not considered essential functions of the machine control module.
[0045] In one embodiment, the main perfusion circuit includes a reservoir 1, a main circulation pump 2, an oxygenator 3, a heat exchanger 4, a main circuit bubble trap 5, an arterial pressure and flow monitoring unit 10, a venous return line 12, and a sampling port 24, forming a main circuit that circulates in a closed loop through the ex vivo organ 11; the universal genetic modification module 6, the external blood purification bypass module 25, the urine management module 18, and the supplemental fluid branch are all connected to the main perfusion circuit as shown in the figure.
[0046] In one embodiment, the universal gene-modification module 6 comprises a vector cartridge 7, a metering pump 8, and a vector injection and mixing unit 9. The vector cartridge 7 is used to contain one or more gene-modified vectors; the metering pump 8 is used to deliver the vector from the vector cartridge 7 to the vector injection and mixing unit 9; the vector injection and mixing unit 9 is connected in series with the main perfusion circuit, so that the vector is directly added to the perfusion fluid before entering the ex vivo organ 11.
[0047] The vector cartridge 7 can load vectors such as lentiviruses, adeno-associated viruses, adenoviruses, siRNAs, shRNAs, antisense oligonucleotides, lipid nanoparticles, CRISPR-Cas RNPs, editor mRNA / sgRNAs, plasmids, or protein complexes. These vector types are optional and do not add any new hardware components. The metering pump 8 can perform single-dose, fractional-dose, continuous, or pulsatile dosing.
[0048] During the drug administration and effective exposure phases, the liquid intake isolation valve 13 and the liquid return isolation valve 17 are closed, and the bypass pump 14 is stopped, allowing the carrier to enter the isolated organ 11 via the carrier injection mixing unit 9 and the arterial pressure and flow monitoring unit 10, without passing through the external blood purifier 15. The preferred carriers for normothermic mechanical perfusion of porcine kidney are LV-shB2M and LV-shCIITA. Both carriers are placed separately or together in the carrier cartridge 7 and directly added to the perfusion fluid via the quantitative drug delivery pump 8 and the carrier injection mixing unit 9, primarily targeting the glomerular endothelial vascular bed reached via the renal artery.
[0049] In one embodiment, the external blood purification bypass module 25 is a branch connected in parallel with the main perfusion circuit, consisting of a liquid intake isolation valve 13, a bypass pump 14, an external blood purifier 15, a bypass bubble trap 16, a return liquid isolation valve 17, and a blood purification waste collection bag 20. The bypass draws liquid from the venous return line 12, and the purified liquid returns to the reservoir 1. The external blood purifier 15 can be a hemodialysis, hemofiltration, hemodiafiltration, or CRRT device.
[0050] During the drug administration and effective exposure phase, the liquid extraction isolation valve 13 and the liquid return isolation valve 17 are closed, and the bypass pump 14 is stopped, keeping the genetically modified vector within the main perfusion circuit. After the preset exposure is completed, the liquid extraction isolation valve 13 and the liquid return isolation valve 17 are opened, and the bypass pump 14 is started to support long-term maintenance or removal of residual components that can be removed by the external blood purifier 15. When the external blood purifier 15 stops working or needs to be replaced, closing the liquid extraction isolation valve 13 and the liquid return isolation valve 17 isolates the entire external blood purification bypass module 25; the main circulation pump 2 continues to drive the main perfusion circuit, ensuring that the perfusion of the ex vivo organ 11 is not interrupted due to the bypass being discontinued.
[0051] In one embodiment, the urine management module 18 is connected to the isolated organ 11 via a urine inflow line and to the reservoir 1 via a urine return line. During prolonged porcine kidney perfusion, urine returns to the reservoir 1 via the urine management module 18 to maintain the fluid circulation in the illustrated loop. A replenishment bag 19 is connected to the reservoir 1 via a replenishment line. When additional fluid is needed in the loop, replenishment fluid is supplied to the reservoir 1 via the replenishment bag 19.
[0052] In one embodiment, a gas supply unit 22 is also included, which is connected to the oxygenator 3 via a gas passage to supply the oxygenator 3 with the gas required for filling.
[0053] In one embodiment, the temperature regulation module 23 is connected to the heat exchanger 4 via a temperature control pipeline as shown in the figure to regulate the temperature of the perfusion fluid in the main perfusion loop. The candidate temperature for the cryogenic mechanical perfusion state is 4 to 20°C, used for maintaining low temperature before and after organ access or gene modification; the candidate temperature for the room temperature mechanical perfusion state is 32 to 38°C, used to restore organ metabolism and provide the temperature conditions required for the gene modification vector to function. When switching from a cryogenic state to a room temperature state or returning from a room temperature state to a cryogenic state, the coordination control module 21 controls the temperature regulation module 23 to gradually change the heat exchange state of the heat exchanger 4.
[0054] In one embodiment, the coordination control module 21 connects the main circulation pump 2, the universal genetic modification module 6, the arterial pressure and flow monitoring unit 10, the bypass pump 14, the urine management module 18, and the temperature regulation module 23 via dashed lines in the figure. The arterial pressure and flow monitoring unit 10 provides the coordination control module 21 with main perfusion circuit operation information, and the coordination control module 21 controls and coordinates the main circulation pump 2, the universal genetic modification module 6, the bypass pump 14, the urine management module 18, and the temperature regulation module 23 in a preset sequence; the dashed lines in the figure represent control signals.
[0055] The machine includes at least the following operating states: main perfusion state, with the main circulation pump 2 running and the general genetic modification module 6 stopped; drug delivery state, with the metering pump 8 running and the blood purification bypass module isolated; effective exposure state, with the main perfusion circuit running continuously and the blood purification bypass module kept closed; long-term maintenance state, with drug delivery stopped and the bypass pump 14 restarted; and termination state, with drug delivery stopped and the perfusion fluid temperature changed as needed via the temperature regulation module 23.
[0056] The perfusion machine used for in vitro gene editing operates as follows:
[0057] Step S1: Connect the reservoir 1, main circulation pump 2, oxygenator 3, heat exchanger 4, main circuit bubble trap 5, carrier injection and mixing unit 9, arterial pressure and flow monitoring unit 10, venous return line 12 and excised organ 11 to form a closed main perfusion circuit.
[0058] Step S2: Connect the gas supply unit 22 to the oxygenator 3, the temperature regulation module 23 to the heat exchanger 4, the urine management module 18 to the isolated organ 11 and the reservoir 1, and connect the supplementary fluid bag 19 to the reservoir 1.
[0059] Step S3: Depending on whether long-term perfusion is required, connect the external blood purification bypass module 25 and confirm that the bypass includes, in sequence, a liquid extraction isolation valve 13, a bypass pump 14, an external blood purifier 15, a bypass bubble trap 16, a return liquid isolation valve 17, and a blood purification waste liquid collection bag 20.
[0060] Step S4: Start the main circulation pump 2, the air supply unit 22 and the temperature regulation module 23 to establish the main perfusion circulation; if blood purification is required in advance, open the liquid extraction isolation valve 13 and the liquid return isolation valve 17 and start the bypass pump 14.
[0061] Step S5: Enter the drug delivery state, close the liquid extraction isolation valve 13 and the liquid return isolation valve 17 and stop the bypass pump 14, place the gene-modified vector in the vector cartridge 7, and deliver it to the vector injection mixing unit 9 by the quantitative drug delivery pump 8.
[0062] Step S6: Keep the main circulation pump 2 running during effective exposure, so that the carrier enters the ex vivo organ 11 through the arterial pressure and flow monitoring unit 10 along with the perfusion fluid; the external blood purification bypass module 25 is kept isolated.
[0063] Step S7: After completing the preset effective exposure, stop the quantitative drug delivery pump 8, open the liquid intake isolation valve 13 and the liquid return isolation valve 17, and start the bypass pump 14 to put the machine into a long-term maintenance state.
[0064] Step S8: During the long-term maintenance process, urine is returned to the reservoir 1 via the urine management module 18; when fluid replenishment is needed, fluid replenishment is input into the reservoir 1 via the replenishment bag 19.
[0065] Step S9: After reaching the preset perfusion time, the drug administration and blood purification are terminated. The temperature of the perfusion fluid is adjusted via the temperature control module 23, and a sample is obtained through the sampling port 24. The genetic modification results are confirmed using an external method matched to the specific vector.
[0066] The machine operating conditions for the perfusion machine used for in vitro gene modification are shown in Table 1:
[0067] Table 1 Critical Operating Conditions
[0068] Parameter Items Candidate range or state Corresponding diagram structure illustrate ambient temperature perfusion 32 to 38℃ Temperature control module, heat exchanger Used in organ NMP and carrier action phase Low temperature infusion 4 to 20℃ Temperature control module, heat exchanger Used for cryoprotection before and after accession or gene modification Main circuit pressure Based on organ type; candidate levels are 50 to 90 mmHg for pig kidneys and 40 to 80 mmHg for human kidneys. Main circulation pump, monitoring unit The main circulation pump provides the flow, and the monitoring unit acquires pressure and flow information. Gene-modified vectors Viruses, nucleic acids, LNPs, RNPs, mRNA / sgRNA, etc. Carrier Card Box The carrier can be replaced as needed. Administration method Once, in stages, continuously, or in pulses Dosing pump, infusion mixing unit Carrier directly added to perfusion fluid Effective exposure Determined by vector; lentivirus candidates 2 to 6 hours Universal genetic modification module, liquid intake isolation valve and liquid return isolation valve Isolate blood purification bypass module during exposure Long-term maintenance Candidates 24 to 72 hours or longer External blood purification bypass module, urine management module, and fluid replacement bag Restore external blood purification bypass after discontinuing drug administration Blood purification methods Dialysis, hemofiltration, diafiltration or CRRT External blood purifier The external blood purifier is located in the parallel bypass.
[0069] The perfusion machine for in vitro gene editing of the present invention has the following features:
[0070] The main perfusion circuit has a clear and continuous connection sequence. Even when the external blood purification bypass module 25 is closed or deactivated, the main circulation pump 2 can still maintain perfusion of the ex vivo organ 11. The universal genetic modification module 6 is located after the main circuit bubble trap 5 and before the arterial pressure and flow monitoring unit 10, allowing the load to be directly added to the perfusion fluid after oxygenation and heat exchange and before entering the ex vivo organ 11. The external blood purification bypass module 25 uses a liquid intake isolation valve 13 and a liquid return isolation valve 17 for double-end isolation. This prevents the load from entering the external blood purifier 15 during drug administration and effective exposure, while restoring blood purification during long-term maintenance.
[0071] The coordination control module 21 maintains the main perfusion, drug delivery, effective exposure, long-term maintenance, urine reflux, supplemental fluid input, and temperature regulation tissues in a continuous operating state, while not setting the modification results of specific targets as a condition for the machine to function. The machine structure does not limit the load principle; the load type is changed through the carrier cartridge 7, while the main perfusion circuit, organ pre-drug delivery location, and blood purification bypass connection remain unchanged.
[0072] It should be noted that the payload in the vector cartridge 7 of this invention can be replaced with one or more of lentivirus, AAV, adenovirus, siRNA, shRNA, antisense oligonucleotide, LNP-mRNA, CRISPR-Cas RNP, editor mRNA / sgRNA, plasmid, or protein complex, while the three-component structure of the universal gene modification module 6 remains unchanged. The external blood purifier 15 can be replaced with a dialyzer, hemofilter, dialysis filtration device, or CRRT device, while the connection order of the liquid intake isolation valve 13, bypass pump 14, bypass bubble trap 16, and return isolation valve 17 remains unchanged. The ex vivo organ 11 can be a kidney, liver, lung, heart, pancreas, or other ex vivo organs 11 with a vascular inlet and return outlet; the basic connection relationship of the main perfusion circuit, the pre-organ gene modification module 6, and the parallel blood purification bypass module 25 remains unchanged.
[0073] Specific examples have been used to illustrate the principles and implementation methods of this invention. The descriptions of the above embodiments are only for the purpose of helping to understand the method and core ideas of this invention. Furthermore, those skilled in the art will recognize that, based on the ideas of this invention, there will be changes in the specific implementation methods and application scope. Therefore, the content of this specification should not be construed as a limitation of this invention.
Claims
1. A perfusion machine for in vitro gene modification, characterized in that: The device includes a main perfusion circuit, a universal genetic modification module, an external blood purification bypass module, a urine management module, a temperature regulation module, and a coordination control module. The main perfusion circuit is used to continuously supply fluid to the isolated organ. The universal genetic modification module is connected to the main perfusion circuit. The external blood purification bypass module is used to communicate with the main perfusion circuit and support long-term perfusion. The urine management module is also connected between the isolated organ and the main perfusion circuit. The coordination control module is signal-connected to the main perfusion circuit, the universal genetic modification module, the external blood purification bypass module, the urine management module, and the temperature regulation module. The temperature control module is used to regulate the temperature of the perfusion fluid in the main perfusion circuit.
2. The perfusion machine for in vitro gene modification according to claim 1, characterized in that: The main perfusion circuit includes a reservoir, a main circulation pump, an oxygenator, a heat exchanger, a main circuit bubble trap, and an arterial pressure and flow monitoring unit connected in sequence. The end of the arterial pressure and flow monitoring unit is connected to the excised organ. The perfusion fluid of the excised organ is returned to the reservoir through a venous return line to form a closed-loop main circulation circuit through the excised organ. A sampling port is provided on the venous return line.
3. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: The universal gene modification module includes a vector cartridge, a quantitative drug delivery pump, and a vector injection and mixing unit. The vector is delivered from the vector cartridge to the vector injection and mixing unit via the quantitative drug delivery pump. The vector injection and mixing unit is connected in series after the main loop bubble trap.
4. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: The external blood purification bypass is connected in parallel to the venous return line. The external blood purification bypass module includes a liquid extraction isolation valve, a bypass pump, an external blood purifier, a bypass bubble trap, and a return liquid isolation valve connected in sequence. A blood purification waste liquid collection bag is connected to the external blood purifier.
5. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: The urine management module includes a urine inflow pipeline and a urine return pipeline. The urine inflow pipeline receives urine produced by the excised organ and returns it to the reservoir via the urine return pipeline.
6. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: It also includes a replenishment fluid branch, which uses a replenishment fluid bag. The replenishment fluid bag is connected to the reservoir through a replenishment pipeline and replenishes the reservoir with fluid.
7. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: It also includes a gas supply unit, which is connected to the oxygenator via a gas passage and is used to supply the oxygenator with the gas required for filling.
8. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: The temperature regulation module is connected to the heat exchanger via a temperature control circuit, and the temperature of the perfusion fluid in the main injection circuit is adjusted through the heat exchanger.
9. The perfusion machine for in vitro gene modification according to claim 2, characterized in that: The coordination control module is connected to the main circulation pump, the general genetic modification module, the arterial pressure and flow monitoring unit, the urine management module, and the temperature regulation module via signal lines.
10. A perfusion method for in vitro gene modification, applied to the perfusion machine for in vitro gene modification as described in claims 1-9, characterized in that, Includes the following steps: Step 1: Connect the reservoir, main circulation pump, oxygenator, heat exchanger, main loop bubble trap, carrier injection and mixing unit, arterial pressure and flow monitoring unit, venous return line and excised organ to form a closed main perfusion circuit; Step 2: Connect the gas supply unit to the oxygenator, the temperature control module to the heat exchanger, the urine management module to the isolated organ and the reservoir, and connect the supplementary fluid bag to the reservoir; Step 3: Depending on whether long-term perfusion is required, connect an external blood purification bypass module and confirm that the bypass includes, in sequence, a liquid intake isolation valve, a bypass pump, an external blood purifier, a bypass bubble trap, a return liquid isolation valve, and a blood purification waste liquid collection bag. Step 4: Start the main circulation pump, gas supply unit and temperature regulation module to establish the main perfusion circulation; if blood purification is required in advance, open the liquid extraction isolation valve and the liquid return isolation valve and start the bypass pump; Step 5: Enter the drug delivery state, close the liquid extraction isolation valve and the liquid return isolation valve and stop the bypass pump, place the gene modification vector in the vector cartridge, and deliver it to the vector injection and mixing unit by the quantitative drug delivery pump; Step Six: Keep the main circulation pump running during effective exposure, allowing the carrier to enter the isolated kidney along with the perfusion fluid through the arterial pressure and flow monitoring unit; The external blood purification bypass module remains isolated. Step 7: After completing the preset effective exposure, stop the metering pump, open the liquid intake isolation valve and the liquid return isolation valve, and start the bypass pump to put the machine into long-term maintenance mode; Step 8: During the long-term maintenance process, urine is returned to the reservoir via the urine management module; when fluid replacement is needed, fluid is supplied to the reservoir from the fluid replacement bag; Step 9: After the preset perfusion time is reached, the drug administration and blood purification are stopped. The temperature of the perfusion fluid is adjusted through the temperature regulation module, and the sample is obtained through the sampling port. The gene modification results are confirmed by an external method that matches the specific vector.
Citation Information
Patent Citations
Perfusion loop assembly for an ex-vivo liver perfusion and a method for ex-vivo liver perfusion
WO2019141809A1
